Neil Graham
Director/Board Member at ASLAN PHARMACEUTICALS LIMITED
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Carl Firth | M | 51 |
ASLAN Pharmaceuticals Pte Ltd.
 ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | 14 years |
| Adam Tomasi | M | 54 | 7 years | |
| Kathleen Metters | M | 66 |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | 3 years |
| Robert Lisicki | M | 57 | - | |
| Andrew Howden | M | 64 |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | 8 years |
| Kiran Asarpota | M | 45 |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | 14 years |
| Robert Hoffman | M | 58 |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | 6 years |
| Robert Alexander | M | 54 | 7 years | |
| Someit Sidhu | M | 34 | 2 years | |
| Daniel Janney | M | 58 | 7 years | |
| Sandeep Kulkarni | M | 43 | 2 years | |
| Kimberly Ann Davis | F | 56 | 2 years | |
| Michael Howell | M | 47 | 2 years | |
| Simon Green | M | - | 2 years | |
| Arnout Ploos van Amstel | M | 58 | 1 years | |
| Parvinder Thiara | M | 39 | 1 years | |
| Bonnie Bassler | M | 61 | 8 years | |
| Steven James | M | 66 | 8 years | |
| Jennifer Jarrett | F | 53 | 1 years | |
| Eric Andersen | M | 62 | 16 years | |
| Huda Zoghbi | M | 69 | 8 years | |
| Joseph LaRosa | M | 65 | 13 years | |
| Harlan Radford | M | 54 | 3 years | |
| Christine Poon | F | 71 | 14 years | |
| N. Coles | M | 63 | 7 years | |
| Steven Schoch | M | 64 | 1 years | |
| Amit Munshi | M | 56 | 1 years | |
| Paul Walker | M | 49 | 7 years | |
| Robert Andreatta | M | 62 | 6 years | |
| Matthew Davis | M | - |
Tiziana Life Sciences Ltd. (United Kingdom)
 Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 2 years |
| Marion McCourt | F | 64 | 6 years | |
| Theresa Lowry | F | 50 | - | |
| Sally A. Paull | F | - | 8 years | |
| Jana Baskar | M | - | 2 years | |
| Harjit Singh | M | - | - | |
| Marlyn Mathew | F | - | - | |
| Dave Brady | M | - | - | |
| Mark Volpe | M | - | 12 years | |
| Chin Lee | M | 54 | - | |
| Alexandre Kaoukhov | M | - | 2 years | |
| Mary Cromwell | M | - | - | |
| Gary Whale | M | 50 | 1 years | |
| David Henkin | M | - | 16 years | |
| Verender Badial | M | 51 | 1 years | |
| Alex Schwartz | M | - | 3 years | |
| Amy Ladd | M | 66 | 2 years | |
| Maya Bermingham | F | - | 9 years | |
| Kerry K. Reinertsen | M | - | 13 years | |
| Nouhad Husseini | M | - | 13 years | |
| Alan Shuldiner | M | - | 10 years | |
| Stephen Doyle | M | 50 | 6 years | |
| E. Sutherland | M | 54 | 1 years | |
| Johnathan Lancaster | M | - | 5 years | |
| Dolca Thomas | M | 53 | 1 years | |
| Vesna Tosic | M | - | 6 years | |
| Ned Braunstein | M | - | 15 years | |
| Hashan de Silva | M | - | 1 years | |
| Ben Goodger | M | 61 | 8 years | |
| Kiran Nistala | M | 51 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eric M. Shooter | M | 100 | 26 years | |
| Malcolm McComas | M | 68 | 20 years | |
| Murray Goldberg | M | 79 | 20 years | |
| William L. Delaat | M | 72 | 14 years | |
| Ching Feng Sun | M | 61 | 5 years | |
| Marc Tessier-Lavigne | M | 64 | 12 years | |
| David Weinreich | M | - | 7 years | |
| Robert Landry | M | 60 | 11 years | |
| Ferda Cevikbas | M | - | - | |
| Preston Klassen | M | 55 | - | |
| Charles A. Baker | M | 91 | 29 years | |
| Thomas H. Adams | M | 81 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 1 years |
| Robert Alexander Ingram | M | 81 | 1 years | |
| BILL Kessler | M | 57 | 4 years | |
| Stuart A. Kolinski | M | 58 | 10 years | |
| Brett Charlton | M | 67 | 24 years | |
| Javier Cote-Sierra | M | 61 | - | |
| Urvashi Rangan | M | - |
Johns Hopkins Bloomberg School of Public Health
| 5 years |
| Carrie Brownstein | M | 54 | - | |
| Ke Andrew Yuan | M | - | 4 years | |
| Jim Tripp | M | 54 | 5 years | |
| Craig Paterson | M | 59 | 3 years | |
| Kevin Schutz | M | - |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 1 years |
| Charlie Sanders | M | 91 |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 10 years |
| Christopher Cabell | M | 54 | - | |
| Phillip Gutry | M | 50 | 3 years | |
| Ed Rayner | M | - | 2 years | |
| Jerry Wollman | M | - |
Johns Hopkins Bloomberg School of Public Health
| 1 years |
| Manisha A. Narasimhan | M | 48 | 7 years | |
| Michael Weiss | M | 58 | - | |
| Michael A. Recny | M | - |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 12 years |
| Pamela A. Trail | M | 68 | 7 years | |
| Lim Damien | M | 61 | 5 years | |
| Jay Markowitz | M | 61 | 3 years | |
| E. Gary Cook | M | 79 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Jesper Gromada | M | - | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 72 | 75.79% |
| Singapore | 11 | 11.58% |
| Australia | 7 | 7.37% |
| Bermuda | 3 | 3.16% |
| Israel | 2 | 2.11% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Neil Graham
- Personal Network